Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe Chronic Kidney Disease

NCT05374291 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT05374291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05374291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe Chronic Kidney Disease
Lead sponsor
University Medical Center Groningen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 8, 2022
Completion date
July 31, 2027
Enrollment
1,750 (estimated)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

death, heart failure, kidney disease, chronic, kidney failure, renal transplant failure